

# LifePearl™

Microspheres

## BROAD TREATMENT OPTIONS<sup>1</sup>


Loadable with 4 chemotherapeutic drugs<sup>1</sup>:

- Doxorubicin
- Idarubicin
- Epirubicin
- Irinotecan



## PRECISE CALIBRATION

LifePearl™ microspheres have a precise calibration<sup>3</sup> that may lead to a more targeted embolization.



## LONG SUSPENSION TIME

LifePearl™ microspheres offer enhanced suspension characteristics.<sup>2,3</sup>


UP TO  
6 MIN



Veloso et al. reported results from one of the largest multicentric cohorts of **unresectable HCC patients (n=580)** treated with **LifePearl™ microspheres** to date<sup>5</sup>:

**OVER  
4 YEARS**

**median Overall Survival  
50.8 months [95% CI 44.7-NE]<sup>5</sup>**




**60.1%**

**complete response rate exceeding what is reported in previous studies<sup>7,8,9</sup>**


**Complete Response and Partial Response at 3 months** is a **positive predictive indicator of Overall Survival<sup>5</sup>** - hence the importance of Complete Response as TACE outcome.

Overall Survival (months) - Multivariable Stepwise Selection Model (variables with univariable p<=0.20 entered) stepwise selection: Model Entry and Stay p-values of p=0.35 and p=0.20, respectively.





A real world multicentric prospective registry including 97 patients with HCC treated with LifePearl™ Microspheres demonstrated a low level of HPB toxicities with 15.5%.<sup>6</sup>



AE	Events, n	Patients, n
All grade ≥ 3 AEs	21	13
Grade ≥ 3 AEs that occurred in >1 patient		
Abdominal pain	6	6
Fatigue	3	3
Hypertension	3	3

Hepatobiliary toxicity*	Events, n*
Biloma	9
Portal vein thrombosis	9
Bile duct dilations	9
Portal vein branch narrowing	2


\* Assessed from imaging, not reported as AEs  
 \* Number of events out of a total of 187 procedures

1.1. LifePearl IFU (January 2018)  
 2. Perotti PI, et al. *Anti-cancer Drugs*. 2017;28(1):1-11.  
 3. De Baere T, et al. *J Vasc Interv Radiol*. 2010;21(11):1611-1618.  
 4. *data on file* - Ref. TR16-158  
 5. Velloso Gomes P, et al. *Cardiovasc Intervent Radiol*. 2012;34(6):436-446.  
 6. De Baere T, et al. *Cancers*. 2020;12:3405.  
 10. Gullu B, et al. *J Hepatol*. 2012;56:609-17.


# HIGH ELUTION RATES

LifePearl™ microspheres have shown higher percentage of drug elution than the rest of our competitors.<sup>2-3</sup>


LifePearl™ microspheres loaded with doxorubicin, idarubicin, epirubicin or irinotecan offer a steady, continuous and lasting elution over an extended period of time.<sup>2-4</sup>




Irinotecan elution in a Sotax elution system<sup>2</sup>



Elution of 40mg doxorubicin in a dissolution apparatus<sup>3</sup>



Idarubicin elution from LifePearl™ microspheres reaches plateau in approx. 2 hours at 75%<sup>4</sup>



Epirubicin elution from LifePearl™ microspheres reaches plateau in approx. 5 hours at 35%<sup>4</sup>






2. Pereira P, et al. Anticancer Drugs 2016; 27:873-8.  
 3. De Baere J et al. J Vasc Interv Radiol 2016; 27:1475-31  
 4. data on file

# LifePearl™

Microspheres



## ORDERING INFORMATION

LifePearl™ microspheres Sizes (µm)	Volume of microspheres (ml)	Volume of PBS (ml)	Product Codes	Colour
100 ± 25	2	4	BLP25100	Black 
200 ± 50	2	4	BLP25200	Yellow 
400 ± 50	2	4	BLP25400	Blue 

LifePearl™ microspheres are indicated for the embolization of blood vessels supplying primary hypovascular tumors or metastases in the liver. Note: LifePearl™ microspheres can be loaded with chemotherapeutic drugs (Doxorubicin, Mitomycin, Epirubicin and Irinotecan). When used for drug loading, drug loading should be done under a physician's direction, choice and responsibility, based on type and dose of drug most beneficial to the patient. LifePearl™ microspheres are not available for sale in all countries. This information is provided only in respect to markets where this product is approved or cleared. The use of the LifePearl™ microspheres device in combination with drugs is not cleared or approved in the U.S.A. by the Food and Drug Administration. LifePearl™ microspheres are not approved in Canada. Please contact your Terumo local sales representative for more information. LifePearl™ microspheres are manufactured by Microvention and exclusively distributed by Terumo Europe NV in EMEA region. Microvention is a registered trademark of Microvention, Inc. LifePearl™ microspheres are a registered trademark of Terumo, Inc. Scientific and clinical data related to this document are on file at Microvention, Inc. DC Bead is a trademark and/or registered trademarks of Biocompartibles UK Limited, a BTG International group company. HepaSphere is a trademark of Merit Medical Systems, Inc. Tandem Embosphere is a trademark of Varian Medical Systems, Inc. Refer to Instructions for Use for additional information. © 2024 Terumo Corporation. Manufacturer Microvention Europe SARL - 30 bits, rue du Vieil Abreuvoir 78100 Saint-Germain-en-Laye FRANCE - Tel: +33(0)1 39 21 77 64 - Fax: +33(0)1 39 21 16 01.



Terumo Corporation  
+81 33374 8111

Terumo Europe NV  
+32 16 38 12 11

Terumo  
Interventional  
+33 1 47

Terumo Europe NV  
Africa Business Division  
+32 16 38 13 08

Terumo Europe NV  
Business Sales Division  
Belgium:  
0800 14468  
The Netherlands:  
0800 0231938

Terumo Europe NV  
+32 16 38 12 11

Österreich  
+43 2236 378020

Terumo Deutschland GmbH  
Schweiz/italien  
+41 56 419 10 10

Terumo Europa España SL  
+34 902 10 12 98

Terumo France S.A.S.  
+33(0) 800 4090 47

Terumo Sweden AB  
+46 3174 85 880

Terumo Middle East FZE  
+971 4 292 0200

Terumo UK Ltd  
+44 1276 480440

Terumo BCT Fdhi Chahar Daghstan  
va Hozmetdar A.S.  
+90 216 645 92 00

Terumo Poland Sp. z o.o.  
+48 22 120 16 00

Manufacturer Microvention Europe SARL  
30 bits, rue du Vieil Abreuvoir  
78100 Saint-Germain-en-Laye France  
+33(0)1 39 21 77 46

© Registered trademark  
Published by Terumo Europe NV

www.terumo-europe.com

891708-04-01Y